NASDAQ:ATOS Atossa Therapeutics (ATOS) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free ATOS Stock Alerts $1.52 +0.02 (+1.33%) (As of 05:32 PM ET) Add Compare Share Share Today's Range$1.45▼$1.5750-Day Range$0.98▼$2.1052-Week Range$0.59▼$2.31Volume852,971 shsAverage Volume1.40 million shsMarket Capitalization$190.46 millionP/E RatioN/ADividend YieldN/APrice Target$4.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Atossa Therapeutics alerts: Email Address Atossa Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside196.1% Upside$4.50 Price TargetShort InterestBearish9.86% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.05Based on 2 Articles This WeekInsider TradingAcquiring Shares$44,250 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.28) to ($0.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.39 out of 5 starsMedical Sector768th out of 907 stocksPharmaceutical Preparations Industry361st out of 422 stocks 3.5 Analyst's Opinion Consensus RatingAtossa Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAtossa Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.86% of the outstanding shares of Atossa Therapeutics have been sold short.Short Interest Ratio / Days to CoverAtossa Therapeutics has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Atossa Therapeutics has recently increased by 16.95%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAtossa Therapeutics does not currently pay a dividend.Dividend GrowthAtossa Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATOS. Previous Next 2.8 News and Social Media Coverage News SentimentAtossa Therapeutics has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Atossa Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 22 people have searched for ATOS on MarketBeat in the last 30 days. This is a decrease of -15% compared to the previous 30 days.MarketBeat Follows13 people have added Atossa Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 63% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atossa Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $44,250.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.80% of the stock of Atossa Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 12.74% of the stock of Atossa Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Atossa Therapeutics are expected to decrease in the coming year, from ($0.28) to ($0.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atossa Therapeutics is -6.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atossa Therapeutics is -6.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtossa Therapeutics has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Atossa Therapeutics Stock (NASDAQ:ATOS)Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Read More ATOS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATOS Stock News HeadlinesApril 13, 2024 | insidertrades.comJonathan Finn Buys 25,000 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) StockApril 24, 2024 | americanbankingnews.comAtossa Therapeutics (NASDAQ:ATOS) Shares Pass Above 200 Day Moving Average of $1.00April 25, 2024 | DTI (Ad)What is the 72-Hour Profit Surge?One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…April 17, 2024 | americanbankingnews.comAtossa Therapeutics (NASDAQ:ATOS) Given Buy Rating at HC WainwrightApril 16, 2024 | insidermonkey.com5 Micro-Cap Healthcare Stocks Insiders Are BuyingApril 15, 2024 | markets.businessinsider.comPromising Synergies: Atossa Therapeutics’ Advances in ER+/HER2- Breast Cancer TreatmentApril 15, 2024 | proactiveinvestors.comAtossa Therapeutics announces breast cancer trial evaluating lead asset in combination with Eli Lilly drugApril 15, 2024 | globenewswire.comAtossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast CancerApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 11, 2024 | globenewswire.comAtossa to Participate in Noble Capital Markets Emerging Growth Healthcare ConferenceApril 10, 2024 | markets.businessinsider.comAtossa Therapeutics Poised for Growth with Promising Breast Cancer TreatmentApril 10, 2024 | markets.businessinsider.comAtossa Therapeutics: Strong Buy on Promising EVANGELINE Study Results and Z-endoxifen Efficacy PotentialApril 9, 2024 | msn.comAtossa stock climbs 11% on breast cancer drug dataApril 9, 2024 | proactiveinvestors.comAtossa Therapeutics reports positive data from breast cancer treatment trialApril 9, 2024 | globenewswire.comAtossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-EndoxifenApril 3, 2024 | finance.yahoo.comAtossa Therapeutics Inc (ATOS) Year-End Earnings: A Comprehensive AnalysisApril 3, 2024 | finanznachrichten.deAtossa Therapeutics, Inc.: Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate UpdateApril 3, 2024 | markets.businessinsider.comOptimistic Outlook for Atossa Therapeutics’ Z-endoxifen in Breast Density and Cancer TherapyApril 2, 2024 | bizjournals.comPSBJ taking nominations for CFO of the Year through April 5April 1, 2024 | msn.comATOS Stock Earnings: Atossa Therapeutics Misses EPS for Q4 2023April 1, 2024 | proactiveinvestors.comAtossa Therapeutics sets sights on breast cancer trial results after strong quarter of clinical milestonesApril 1, 2024 | globenewswire.comAtossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate UpdateMarch 28, 2024 | bizjournals.comIntroducing the Inno Madness BracketMarch 20, 2024 | proactiveinvestors.comAtossa Therapeutics' breast cancer drug milestone sparks investor enthusiasmMarch 19, 2024 | bizjournals.comAtossa Therapeutics back in Nasdaq's good gracesMarch 19, 2024 | proactiveinvestors.comAtossa Therapeutics reports successful five-year treatment outcome for breast cancer patient using (Z)-endoxifenMarch 19, 2024 | globenewswire.comAtossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer PatientSee More Headlines Receive ATOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atossa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today4/25/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATOS CUSIPN/A CIK1488039 Webatossatherapeutics.com Phone(206) 588-0256Fax206-430-1288Employees12Year Founded2009Price Target and Rating Average Stock Price Target$4.50 High Stock Price Target$5.00 Low Stock Price Target$4.00 Potential Upside/Downside+207.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,090,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-31.01% Return on Assets-29.77% Debt Debt-to-Equity RatioN/A Current Ratio17.61 Quick Ratio17.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book2.01Miscellaneous Outstanding Shares125,300,000Free Float115,530,000Market Cap$183.56 million OptionableOptionable Beta1.20 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Steven C. Quay FCAP (Age 73)M.D., Ph.D., Chairman, CEO & President Comp: $1.14MMs. Heather Rees (Age 52)SVP, Finance & Principal Accounting Officer Ms. Delly Behen P.H.R.Senior Vice President of Administration & HRMr. Eric Van ZantenVice President of Investor & Public RelationsDr. Richard Graydon M.D.Ph.D., Interim Chief Medical OfficerKey CompetitorsVeruNASDAQ:VERUAlimera SciencesNASDAQ:ALIMOmerosNASDAQ:OMERLifecore BiomedicalNASDAQ:LFCRTrevi TherapeuticsNASDAQ:TRVIView All CompetitorsInsiders & InstitutionsPFG Investments LLCBought 23,650 shares on 4/22/2024Ownership: 0.019%Jonathan FinnBought 25,000 shares on 4/10/2024Total: $44,250.00 ($1.77/share)View All Insider TransactionsView All Institutional Transactions ATOS Stock Analysis - Frequently Asked Questions Should I buy or sell Atossa Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atossa Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATOS shares. View ATOS analyst ratings or view top-rated stocks. What is Atossa Therapeutics' stock price target for 2024? 2 Wall Street research analysts have issued 1 year price objectives for Atossa Therapeutics' stock. Their ATOS share price targets range from $4.00 to $5.00. On average, they expect the company's stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 196.1% from the stock's current price. View analysts price targets for ATOS or view top-rated stocks among Wall Street analysts. How have ATOS shares performed in 2024? Atossa Therapeutics' stock was trading at $0.88 on January 1st, 2024. Since then, ATOS stock has increased by 72.7% and is now trading at $1.52. View the best growth stocks for 2024 here. Are investors shorting Atossa Therapeutics? Atossa Therapeutics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 12,350,000 shares, an increase of 17.0% from the March 31st total of 10,560,000 shares. Based on an average daily trading volume, of 1,620,000 shares, the days-to-cover ratio is currently 7.6 days. View Atossa Therapeutics' Short Interest. When is Atossa Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ATOS earnings forecast. How were Atossa Therapeutics' earnings last quarter? Atossa Therapeutics, Inc. (NASDAQ:ATOS) posted its earnings results on Monday, April, 1st. The company reported ($0.06) EPS for the quarter. When did Atossa Therapeutics' stock split? Atossa Therapeutics's stock reverse split on the morning of Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 19th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What is Steven C. Quay's approval rating as Atossa Therapeutics' CEO? 8 employees have rated Atossa Therapeutics Chief Executive Officer Steven C. Quay on Glassdoor.com. Steven C. Quay has an approval rating of 53% among the company's employees. This puts Steven C. Quay in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 29.0% of employees surveyed would recommend working at Atossa Therapeutics to a friend. What other stocks do shareholders of Atossa Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Atossa Therapeutics investors own include AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Heat Biologics (HTBX), Vaxart (VXRT), Biocept (BIOC), MannKind (MNKD), Biopharmx (BPMX), Daré Bioscience (DARE), OPKO Health (OPK) and Nokia Oyj (NOK). Who are Atossa Therapeutics' major shareholders? Atossa Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include PFG Investments LLC (0.02%). Insiders that own company stock include Gregory L Weaver and Jonathan Finn. View institutional ownership trends. How do I buy shares of Atossa Therapeutics? Shares of ATOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATOS) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeThe World's First "$20 Trillion Drug?"Behind the MarketsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
